Chronic autonomic neuropathies …

Louis H Weimer MD

Peripheral Neuropathies

Updated 04.07.2024
Released 02.06.2002
Expires For CME 04.07.2027

Chronic autonomic neuropathies

Author: Louis H Weimer MD

See Contributor Disclosures

Chronic autonomic neuropathies

In This Article

Quick Link

Introduction

Overview

The authors review the clinical presentation, diagnosis, pathogenesis, and management of chronic autonomic neuropathies. Autonomic neuropathies are acquired or inherited diseases resulting from a disturbance of the peripheral autonomic nervous system. New treatments have emerged for hereditary neuropathies that are associated with autonomic dysfunction including hereditary transthyretin neuropathy.

Historical note and terminology

Chronic autonomic neuropathy is an inclusive term used to describe diseases resulting from distinct etiologies, but that have in common pathology of the peripheral autonomic nervous system.

Clinical manifestations

Presentation and course

As with acute autonomic neuropathies, chronic autonomic dysfunction shares several common clinical features and underlying causes. Patterns vary depending on relative involvement of distal sympathetic, cholinergic, or adrenergic systems (Table 1). All organ systems have some autonomic fiber innervation, so the clinical manifestations vary depending on the pattern of organ system involvement and the pathological cause. The typical clinical features of chronic autonomic neuropathies are indicated below. Contrary to common belief, most causes of sensorimotor or small fiber neuropathy affect autonomic fibers as well. In many cases, manifestations are length-dependent and affect mainly or exclusively distal sites. Loss of distal sweating, trophic changes, and vasomotor and temperature regulation consequences are evident. The vast majority of those conditions are not discussed in this section. Instead, entities that have disproportionate or exclusive autonomic manifestations are detailed.

Table 1. Clinical Features of Autonomic Nervous System Failures

Distal sympathetic failure
	• difficulty keeping feet warm • increased perspiration (early) • anhidrosis (late) • rubor • acrocyanosis • peripheral pain • peripheral edema
Cholinergic failure
	• anhidrosis • atonic bladder • Adie pupil • alacrima • cardiovagal failure • constipation • impotence • detrusor areflexia
Adrenergic failure
	• lightheadedness • tiredness or weakness • cognitive impairment on standing • blurred vision • tremulousness • pallor • anxiety • tachycardia • palpitations • feeling clammy • nausea • stress incontinence

Idiopathic distal small-fiber neuropathy. This chronic peripheral autonomic neuropathy is characterized by superficial burning pain on the sole and toe pads. It may be a manifestation of impaired glucose regulation or may be truly idiopathic. Clinical findings include allodynia, deep aching pain, sympathetic vasomotor changes, pallor alternating with rubor, cyanosis, and mottling (50). Examination usually reveals normal strength and mild impairment of sensation distally with typically normal deep tendon reflexes. Diagnosis is made by clinical examination and laboratory exclusion of the many causes of small-fiber neuropathy, and by skin biopsies (24). Some may be undetected hereditary neuropathies or may have impaired glucose tolerance. In patients with neuropathy of undetermined etiology, 36% have impaired glucose tolerance. Patients with impaired glucose tolerance have earlier, milder forms of neuropathy in comparison to diabetic neuropathy, indicating a possible correlation between the severity of glucose dysregulation and the severity of neuropathy (66). Sodium channel mutations (Na(v)1.7 sodium channel mutations) have been associated with rare painful dysautonomic syndromes such as primary erythromelalgia and paroxysmal extreme pain disorder. Small fiber neuropathy with autonomic symptoms and chronic nonparoxysmal pain have been described in patients harboring gain-of-function mutations in Na(v)1.7 channel (16).

Pure cholinergic autonomic neuropathy. This disorder includes the following diseases:

Lambert-Eaton myasthenic syndrome. This entity is an acquired presynaptic disorder of neuromuscular transmission that involves reduction in the release of acetylcholine and occurs in about 3% of patients with small-lung cancer. Primary manifestations are characterized by proximal muscle weakness and reduced or absent deep tendon reflexes; autonomic symptoms are evident in 80% of patients (63). Common autonomic symptoms include dry mouth, impotence, constipation, orthostatic hypotension (adrenergic), and urinary difficulties (62; 45). Voltage-gated calcium channel antibodies, present in the vast majority of cases, affect autonomic ganglia as well as neuromuscular junction acetylcholine transmission.

Chagas disease. This condition is caused by Trypanosoma cruzi infection and is endemic in parts of South America. The disease is often asymptomatic but may be associated with parasympathetic greater than sympathetic neuropathy. Pathologically, Chagas disease is characterized by lymph node enlargement and inflammatory changes in cardiac muscle, skeletal muscle, nerve, and autonomic ganglia. A study that tracked 321 Brazilian Chagas disease patients found basic autonomic HR variability measures were not independent markers of 14-year mortality (55).

Chronic idiopathic anhidrosis. This disorder is an acquired selective and generalized loss of sweating without adrenergic or cardiovagal failure. Onset is often subacute and may be postviral; patients typically have near but not complete global sweating loss but no other findings. Most retain small patches of sweating that are insufficient for temperature control. These patients are heat intolerant and become hot, dizzy, flushed, dyspneic, and weak when exposed to heat or exercise. Orthostatic hypotension is absent. About half slowly improve and regain sweating, but many do not. The condition is more common in horses. One group found a candidate mutation in a potassium channel subunit gene (KCNE4) (57).

Sporadic primary amyloid neuropathy. A generalized acquired small fiber painful and autonomic neuropathy clinically characterizes primary amyloid neuropathy, also known as AL amyloid. It usually begins in the feet, with a predominance of pain and temperature loss, autonomic failure, and weight loss. It is generally a disease of middle to older age persons. Autonomic failure consisting of orthostatic hypotension, with presyncope or syncope, is a prominent feature early in the illness course and may be severe (50). Anhidrosis, impotence, and gastroparesis are common. Amyloidosis may be associated with polyneuropathy in 20% of subjects with light chain amyloid, and 25% of subjects may have carpal tunnel syndrome. In addition to involvement of the peripheral nervous system, virtually all other organs can be involved in both acquired and familial amyloidosis. It is characterized pathologically by Congo red positive deposits in connective tissue and vessel walls resulting in red-green birefringence under polarized light; however, diagnostic biopsy material may be problematic to find even in suspected cases. Fat pad, rectal, or organ biopsies are often performed. In some cases, muscle and nerve biopsy is needed to detect the amyloid and initiate treatment. Paraproteinemia, multiple myeloma, or light chain disease typically underlies the condition. The median survival was 13 to 35 months (28). Newer approaches to chemotherapy and bone marrow or stem cell transplant have improved survival. This topic is covered in more detail in other sections.

Familial amyloid polyneuropathy. This entity is typically an autosomal-dominant disorder. Classification is based on mutations of three proteins: transthyretin (TTR), apolipoprotein A1, and gelsolin. Most commonly inherited mutations occur in the transthyretin (prealbumin) gene; more than 100 mutations (mainly missense point mutations) of the transthyretin gene have been described. In TTR-related familial amyloid polyneuropathy, formerly known as type 1 familial autonomic neuropathy, the most frequent mutation is Val30Met (18q11.2-q12.1). As in the sporadic form, autonomic symptoms are common and severe in some, but not all mutations. Manifestations include orthostatic hypotension, distal anhidrosis, impotence, urinary retention, and gastrointestinal dysfunction. In Thr49Ser mutation-related familial amyloid polyneuropathy, patients present with autonomic neuropathy, with a greater degree of cardiac involvement, especially fatal heart failure (06). Glu54Lys mutation has been associated with severe familial amyloid polyneuropathy, early vitreous opacity, and fatal heart failure. In apolipoprotein A1-related familial amyloid polyneuropathy, apolipoprotein A-1 (chromosome 11q23.3) is affected, with a point mutation of Gly26Arg, and presents similarly to TTRP familial amyloid polyneuropathy yet with less autonomic and earlier renal involvement. In gelsolin familial amyloid polyneuropathy, the most common point mutation is asparagine for aspartic acid at residue 187 on the gelsolin gene on chromosome 9. This systemic disorder is distinguished by ocular manifestations, such as corneal opacity due to amyloid infiltration, and involves some degree of autonomic dysfunction (50). Several effective treatments are now FDA-approved in the United States and other countries to treat TTR neuropathy. Vutrisiran (Amvuttra®), patisiran (Onpattro®), eplontersen (Wainua®), and inotersen (Tegsedi®) are approved for the treatment of hereditary TTR neuropathy in adults. Tafamidis (Vyndamax®) and tafamidis meglumine (Vyndaqel®) are FDA-approved for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) but may have benefit for neuropathy or wild-type amyloid. There is some evidence that treatment can halt or possibly improve autonomic neuropathy symptoms and findings in these patients (15; 13).

Other gene mutations can also cause hereditary amyloidosis as noted earlier. Gelsolin mutations in the GSN gene can cause neuropathy, including cranial neuropathy that can mimic motor neuron disease or progressive bulbar palsy.

Metabolic and nutritional causes of autonomic neuropathy.

Diabetic autonomic neuropathy. This entity frequently exists in combination with some degree of somatic nerve involvement. Of patients with neuropathy of undetected etiology, 20% have diabetes (66). Autonomic changes include cardiac parasympathetic impairment, orthostatic hypotension, abnormal sweat patterns, decreased cough response (12), gastric motor abnormalities, bladder dysfunction (up to 50%), and erectile dysfunction. Clinical autonomic failure increases with the length of the illness and age of the patient. With cardiac vagal involvement, patients may develop resting tachycardia and failure to respond to physiological demands. Autonomic neuropathy, particularly when manifested as postural hypotension, may confer substantial morbidity and increased mortality in patients with diabetes (71). Development of techniques to characterize diabetic autonomic neuropathy may improve diagnosis and development of therapies aimed at preventing sudden cardiac death. Despite the importance of cardiac autonomic neuropathy, evidence indicates that many patients with diabetic autonomic neuropathy also have as a comorbidity ischemic cardiac disease that may be asymptomatic due to neuropathy; thus, autonomic neuropathy is likely to be only one of the factors causing the increased mortality in diabetes. The advent of techniques to directly characterize diabetic cardiac autonomic denervation may help elucidate the physiologic significance of this common complication and aid the development of therapeutic strategies for the prevention of sudden cardiac death. In addition, some studies also showed an association of cardiac autonomic neuropathies with chronic kidney disease and albuminuria, and they can be independent predictors of the decline of renal function over the follow-up period in patients with type 2 diabetes (67). Studies indicate that autonomic nerve antibodies are more commonly detected in patients with type 1 diabetes and autonomic neuropathy compared to subjects without autonomic neuropathy (33).

Uremia. This neuropathy is commonly associated with autonomic dysfunction and often improves following renal transplantation. Predominantly large myelinated fibers are injured, but impaired thermal perception is the first abnormal sign in 15% of uremic patients (63).

Nutritional deficiencies. Subacute combined degeneration and alcoholic neuropathy have occasionally been associated with orthostatic hypotension. In alcoholics, vagal parasympathetic dysfunction is prominent, whereas sympathetic function is preserved.

Hereditary sensory autonomic neuropathies. In this heterogeneous group of inherited neuropathies, autonomic dysfunction is present but is confined to distal vasomotor dysfunction and manifested by coldness, discoloration, and anhidrosis in most forms. Type 3 has very prominent autonomic involvement. Cardiovascular reflexes are rarely impaired clinically. Refinement and expansion of genetic markers for this group and hereditary autonomic neuropathies is an ongoing effort (46).

Hereditary sensory autonomic neuropathy type 1. This entity is an autosomal dominant disease with three point mutations identified (C133Y, C133W, V144D - chromosome 9q22.1-q22.3). These result in a defect of the gene (SPTLC1) coding for serine palmitoyltransferase enzyme that catalyzes pyridoxal-5'-phosphate-dependent condensation of L-serine and palmitoyl-CoA to 3-oxosphinganine and results in defects of sphingolipid biosynthesis. The point mutations may lead to accumulation of glucosyl ceramide, leading to neuronal degeneration. A novel missense mutation (G387A) within exon 13 of the same gene SPTLC1 has been discovered (69), yet it is unknown whether this mutation confers a dominant negative effect on the serine palmitoyltransferase enzyme as does the other mutations. Literature shows that hereditary sensory autonomic neuropathy type 1 mutations induce a shift in the substrate specificity of serine palmitoyltransferase, which leads to the formation of the two atypical deoxy-sphingoid bases 1-deoxy-sphinganine and 1-deoxymethyl-sphinganine. Both metabolites lack the C(1) hydroxyl group of sphinganine and can, therefore, neither be converted to complex sphingolipids nor degraded. Consequently, they accumulate in the cell. Elevated deoxy-sphingoid base levels were also found in the plasma of patients with hereditary sensory autonomic neuropathy type 1 and confirmed in three groups of patients with hereditary sensory autonomic neuropathy type 1 and different SPTLC1 mutations. Based on this it has been concluded that hereditary sensory autonomic neuropathy type 1 is caused by a gain of function mutation, which results in the formation of two atypical and neurotoxic sphingolipid metabolites (59). Overexpression of the wild-type allele in a mouse model of hereditary sensory autonomic neuropathy type 1 has reversed the phenotype (22). This finding opens the prospect of possible treatments aimed at reducing the levels of these metabolites. The disorder usually affects young adults starting in the second decade of life and results in distal loss of sensation and sudomotor autonomic reflexes. There is characteristically loss of pain and temperature sensation, and also large fiber dysfunction. This results in foot ulcerations, foot deformities, and Charcot joints (neurogenic osteoarthropathy). Mutilation may also occur in the fingers and hands, and there may be loss of normal bone mineralization. A different mutation in the Serine 331 SPTLC1 gene is also linked to both sensory and autonomic neuropathy and motor neuron disease (26). A patient with early onset sensory and autonomic neuropathy and later bulbar atrophy and fasciculations has been reported (48). A different phenotype in the same gene is located for the SPTLC2 gene on chromosome 14. That condition causes a later onset (over age 20 years and often later) that consists of small fiber painful neuropathy that later progresses to sensory ataxia. Autonomic findings are less of an issue in that alternative form. Additional forms of HSAN (1B-F) are now known but typically affect pain and sensory systems more than autonomic systems.

Hereditary sensory autonomic neuropathy type II. Also known as Moryan disease, this is an autosomal recessive disorder with an onset in early childhood and it affects both large and small sensory fibers. Currently, evidence points to a mutation in a gene termed “HSN2,” a single exon located within intron 8 of the PRKWNK1 gene, chromosome 12p13.33 (43). The defective protein product may affect the development of peripheral sensory neurons or their supporting cells. Hereditary sensory autonomic neuropathy type II involves mainly the impairment of distal function, impairment of pain, and formation of ulcers in the hand and foot. Autonomic function is usually normal, with the exception of abnormal sweating. Nerve conduction shows absent sensory potentials, and the quantitative sudomotor axon reflex test may be abnormal. On nerve biopsy, there is axonal degeneration affecting both sensory and unmyelinated fibers mediating pain and temperature. Several other genes are known to cause HSAN IIB-D but are also typically more sensory than autonomic in nature. Type IID is an autosomal recessive condition caused by mutations in the SCN9A gene. The inability to feel pain as well as extreme pain and erythromelalgia are caused by differing mutations. Autonomic features are typically absent or minimal though some phenotypes have flushing and pupillary abnormalities.

One Japanese study identified a novel homozygous mutation in SCN9A from two families with autosomal recessive hereditary sensory and autonomic neuropathy. The clinical phenotype is characterized by adolescent or congenital onset with loss of pain, temperature sensations, autonomic nervous dysfunction, bone dysplasia, hearing loss, hypogeusia, and hyposmia (74).

Hereditary sensory autonomic neuropathy type III. Also known as familial dysautonomia or Riley-Day syndrome, this condition is an autosomal recessive disorder associated with mutations of the gene coding inhibitor of k light polypeptide gene enhancer in B cells kinase complex-associated protein (IKBKAP - usually T to C transition in intron 20) on chromosome 9q31. This mutation results in a lack of expression of normal protein product (IKAP) in neuronal tissue. The specific role of IKAP is unknown, but current studies suggest that IKAP may be involved in the regulation and activation of stress response through the c-Jun N-terminal kinase signaling pathway, with misregulation of c-Jun N-terminal kinase leading to the inadequate development and low survival of neuronal cells (04). Abnormal migration and maturation of neural crest cells in implicated, especially those destined to be sensory and autonomic neurons. This disorder is almost exclusive in the Ashkenazi-Jewish population--carrier rate is 1 in 30. Onset is at birth and progresses to severe autonomic crises with postural hypotension, hypothermia or fever, fainting, reduced tearing, and vomiting crises. Other clinical features include insensitivity to pain and temperature stimuli but sparing visceral pain, absence of tears, and hypoactive corneal and tendon reflexes. Characteristically, the fungiform papillae on the tongue are absent, and taste may be impaired. Later, subjects develop fingernail dystrophy. Death occurs in over 50% of patients in the first 4 decades. On nerve biopsy, there is loss of unmyelinated axons, usually with sparing of large myelinated axons.

Hereditary sensory autonomic neuropathy type IV. This entity is characterized by congenital insensitivity to pain with anhidrosis. This autosomal recessive disorder is associated with several defects of the gene NTRK1 coding for the neurotrophic tyrosine kinase A/nerve growth factor receptor on chromosome 1q21-q22. There may be impaired binding of nerve growth factor binding to tyrosine kinase A receptor, and NGF-dependent small sensory and sympathetic neurons fail to survive. Clinically the disease begins in infancy with insensitivity to pain, significant joint deformities, self-mutilation, unintentional burns, fever, and absent sweating. Anhidrosis causes episodic fevers, and hyperpyrexia is usually the first sign of the disorder (05). Fingernail dystrophy, hyperkeratosis, and callusing due to the anhidrosis and mental retardation may be observed. Strength and reflexes are usually normal. Death may occur in infancy from impaired temperature regulation. Nerve conduction is usually normal. On histology, small myelinated axons are more severely reduced than large myelinated axons, small dorsal root ganglia neurons are severely reduced, and there is reduced innervation in skin. A large survey of genetic testing results in mostly international French-speaking countries identified seven patients with pathogenic NTRK1 mutations and a mean age of around 10 years (21).

Hereditary sensory autonomic neuropathy type V. This is an extremely rare, predominantly autosomal recessive disorder characterized by congenital insensitivity to pain with partial anhidrosis. The disease begins in infancy with selective loss of pain perception, resulting in acral ulcers and painless fractures. Response to tactile, vibratory, or thermal stimuli is normal (05). The gene of interest is still unknown, but a mutation in the coding region of nerve-growth factor beta on chromosome 1p11.2-p13.2 was associated with hereditary sensory autonomic neuropathy type V symptoms (23). A mutation of the NTRK1 gene may also be the cause of this neuropathy.

Fabry disease. This disorder is an X-linked recessive inborn error of glycosphingolipid metabolism associated with a deficiency of alpha-galactosidase that affects approximately 1:40,000 to 1:60,000 males. It is characterized clinically by development in young boys of premature vascular disease, pure small-fiber polyneuropathy occurring in hands and feet (“Fabry crises”), and hypohidrosis or anhidrosis. The neuropathy involves severely reduced cold perception and sudomotor function (51). Fabry disease has multiple systemic manifestations including renal disease, stroke, cardiac disease, and angiokeratoma of the skin.

Fabry disease

Angiokeratoma of the skin affecting areas of increased pressure on the hip and thigh (arrows). (Contributed by Dr. James Russell.)

Autonomic dysfunction is usually mild, caused by excessive lipid accumulation within the neurons of the autonomic nervous system as well as hypohidrosis and sexual dysfunction. Treatment consists of pain management and enzyme replacement therapy using agalsidase beta (19). Female carriers may have mild small fiber painful neuropathy.

Navajo sensory-autonomic neuropathy. This is characterized by loss of pain and temperature regulation, with loss of distal sweating. Affected infants may have pyrexias of unknown origin coupled with impaired sweating. Some patients may have a normal examination. Affected subjects have skin thickening on the hands and develop painless fractures and a progressive arthropathy. The EMG may be normal or show evidence of a mild neuropathy. Identification of this entity is important to allow enzyme replacement therapy, agalsidase beta (Fabrazyme®), which was FDA approved in 2023.

Infective causes of autonomic neuropathy. Although leprosy, diphtheria, and Lyme disease are associated with autonomic neuropathy, the autonomic nervous system is usually only minimally affected. In leprosy, the R-R intervals are affected in most patients (65). HIV is more commonly associated with sensory and motor neuropathy variants, but may also cause autonomic neuropathy. Many patients with peripheral axonal neuropathy are found to have abnormalities of autonomic reflexes on further testing. Symptoms and findings are similar to those observed in diabetic autonomic neuropathy. Nerve biopsy may show mild CD8-cell infiltration around epi- and endoneurial vessels and loss of myelinated fibers. The CSF protein may be high (130 mg/dL to 1340 mg/dL), with an increase in CSF cellularity.

Toxic and drug-induced autonomic neuropathies. Vincristine causes a dose-related neuropathy, with neurotoxicity observed with a cumulative dose of up to 50 mg. Both parasympathetic and sympathetic clinical features are observed but are generally less symptomatic than sensory symptoms (60). This entity and other forms of chemotherapy-induced neuropathy are discussed in the article on Chemotherapy-induced neuropathies.

Cisplatin causes a dose-dependent pandysautonomia neuropathy, observed in subjects receiving a cumulative dose of up to 825 mg/m2. Other associated features include peripheral neuropathy, ototoxicity, and retrobulbar neuritis (58). Autonomic neurons are typically paradoxically less affected than sensory ganglion neurons and axons.

Paclitaxel and other taxanes cause autonomic neuropathy once the cumulative dose reaches 600 mg/m2 (range 50 mg/m2 to 750 mg/m2). Abnormalities of cardiovagal and adrenergic function are observed. Paclitaxel causes aggregation of microtubules.

Other chemotherapy agents that may cause some autonomic fiber involvement include vinca alkaloids (Vincristine), bortezomib, and possibly other agents.

Acrylamide monomer may be bound at low concentrations in the nervous system. Chronic exposure leads to a sensory neuropathy with excessive sweating due to sympathetic dysfunction. Acrylamide causes chromatolysis in sensory and autonomic ganglia and reduces slow axonal transport. However, evidence indicates that nerve terminal degeneration, rather than axonal damage, may be the primary neuropathological feature of acrylamide neurotoxicity (47). Repetitive exposure to acrylamide causes distal weakness and large fiber sensory loss. Pathologically the acrylamide causes chromatological changes in dorsal root ganglia neurons, and widespread swelling of nerve endings. Purkinje cells may also be a site of acrylamide action.

Other toxic causes of chronic autonomic neuropathy include exposure to vacor, amiodarone, hexacarbons, thallium, and arsenic. Chronic use of amiodarone is associated with neuromyopathy and possibly autonomic failure with orthostatic hypotension (50).

Other conditions that may be associated with autonomic neuropathies.

Holmes-Adie syndrome. This common syndrome is associated with a tonic pupil (initially presents unilaterally but may progress to bilateral), with tendon areflexia. Autonomic neuropathy and, less commonly, peripheral neuropathy have been associated with this syndrome; autonomic dysfunction occurs in 28% to 40% of patients (37). The range of autonomic disturbance includes orthostatic hypotension, impairment of cardiovascular reflexes, chronic diarrhea, and coughing. The combination of tonic pupil, areflexia, and generalized or segmental anhidrosis is also known as the Ross syndrome. Hyperhidrosis has been reported coincident with this syndrome (14). Adie pupil may be associated with different neuropathies, such as hereditary, inflammatory, paraneoplastic, diabetic, amyloid, and alcohol-related neuropathies. Adie pupil may also occur with sensory neuronopathy as part of Sjögren syndrome (52).

Postural orthostatic tachycardia syndrome. This syndrome is associated with postural presyncope, coupled with rapid tachycardia often in excess to the degree of hypotension. Manifestations include postural-induced tachycardia and palpitations that may be coupled with dyspnea, visual blurring, fatigue, exercise intolerance, abdominal cramping, and nausea. The condition may be associated with an infectious prodrome and, thus, represent the chronic sequelae of a form fruste of postviral pandysautonomia or after various viral infections, including COVID-19. The syndrome is detailed in other sections. A minority of patients have coexistent small fiber sensory and autonomic neuropathy.

Celiac disease. Celiac disease is an autoimmune disorder of the small intestine that occurs in genetically predisposed people of all ages. Celiac disease is associated with clinically significant autonomic neuropathy in 2.4% of cases, leading to syncope, presyncope, and postural nausea (28). Autonomic denervation may be related to an autoimmune process and, therefore, this condition does not appear to respond to a strict gluten-free diet (68). The distinction between celiac disease and the more common gluten intolerance or gluten food allergy is critical.

Prion diseases. Prion diseases are typically recognized as rapidly progressive dementing illnesses that also feature myoclonus and cerebellar ataxia. Late-onset hereditary sensory and autonomic neuropathy caused by truncation of prion protein (PrP) and associated with systemic amyloidosis have been described. The symptoms can be disabling and are comparable to familial amyloid polyneuropathy (54).

Autonomic dysfunction is long associated with Guillain-Barré syndrome. In a Mayo clinic retrospective study of 187 patients, 36% had autonomic symptoms (11). Autonomic dysfunction is not seen in chronic inflammatory demyelinating polyneuropathy. However, one case reported tonic pupil in chronic inflammatory demyelinating polyneuropathy, which was different from Aides pupil in that it did not have the light-near dissociation (25). This entity is discussed in the article on acute autonomic neuropathies.

Parkinson disease with significant autonomic insufficiency, including orthostatic hypotension, is a well-known entity that can be problematic to clinically distinguish from multiple system atrophy. Patients with Parkinson disease also have constipation and other autonomic features. Evidence of additional sensory and autonomic neuropathy and cardiac denervation are also known. There is strong evidence that patients with Parkinson disease have reduced epidermal nerve fiber density as opposed to the centrally based multiple system atrophy (30). Both conditions show phosphorylated alpha-synuclein staining in peripheral samples compared to none in controls. Previous studies have shown reduced epidermal nerve fiber density in patients with Parkinson disease supporting small fiber and autonomic neuropathy; however, these combined findings support an accurate separation of patients with Parkinson disease from those with multiple system atrophy (30).

Prognosis and complications

Prognosis depends on the cause of chronic autonomic neuropathy. In general, serious life-threatening complications include an increased incidence of sudden cardiac death and of cerebrovascular events. Sudden cardiac death has been associated with diabetic autonomic neuropathy, although associated cardiac ischemia may equally provoke the event. As with the acute autonomic neuropathies such as Guillain-Barré syndrome, subarachnoid hemorrhage may occur in the setting of hypertension and autonomic instability. Some autonomic conditions have a good prognosis. In postural orthostatic tachycardia syndrome, there is improvement in up to 80%, and 60% return to normal. The prognosis is improved if there is a history of a viral prodrome.

Clinical vignette

A 57-year-old woman presented with burning pain in her feet and then hands for 1 year. The subject had decreased sweating in her limbs, nocturnal diarrhea, and urinary frequency. The patient reported increased bleeding of her gums when brushing her teeth, and had unintentionally lost 35 pounds in 6 months. There was no family history of neuropathy. Mother and aunt had type 2 diabetes mellitus.

On examination strength was normal. Reflexes were decreased at the knees and ankles. There was decreased pin and light touch perception in the legs up to the knee as well as in the distal fingers. Vibration and joint position sense were normal. Rectal examination showed decreased tone.

Nerve conduction studies showed absent sensory responses in the arm and leg as well as decreased motor amplitudes. The case IV vibration detection threshold in the foot was normal, the cool and heat-pain detection thresholds were insensitive (greater than 25 just noticeable difference). The R6, Valsalva, and 30:15 ratios were severely reduced for age. The quantitative sudomotor axon reflex test showed a reduced sweat volume in the forearm and proximal leg with prolonged latencies at both sites. There was no measurable sweat output in the distal leg and foot.

The serum biochemistry was normal except for the presence of an elevated IgG kappa. The nerve biopsy showed amyloid deposits affecting perineurial and endoneurial vessels, consistent with an amyloid polyneuropathy.

Amyloid deposition in amyloid neuropathy

There is increased deposition of the amyloid in the sural nerve endoneurium (arrows). (Contributed by Dr. James Russell.)

Differential diagnosis

The clinician should consider autonomic disorders with central nervous system involvement in subjects who develop autonomic dysfunction. The principal differential diagnosis is between autonomic neuropathies, pure autonomic failure, and multisystem atrophy. These include:

• Multiple systems atrophy (39; 73)
• Parkinson disease
• Olivopontocerebellar atrophy (73)
• Progressive supranuclear palsy (03)
• Autonomic seizures (08; 56)
• Neuroleptic malignant syndrome (41)
• Syringomyelia
• Subacute combined degeneration
• Multiple sclerosis
• Drugs affecting autonomic regulation. Angiotensin-converting enzyme inhibitors, alpha-receptor blockers, calcium channel blockers, beta-blockers, phenothiazines, tricyclic antidepressants, bromocriptine, ethanol, opiates, diuretics, hydralazine, ganglionic blocking agents, nitrates, sildenafil citrate, monoamine oxidase inhibitors.

Table 2. Distinguishing Autonomic Neuropathy From Other Causes of Autonomic Failure

	Idiopathic autonomic neuropathy	Pure autonomic failure	Multiple system atrophy
Lesion	Postganglionic and somatic	Postganglionic and somatic	Preganglionic
Onset	Acute	Insidious	Insidious
Viral prodrome	> 50%	No	No
Clinical findings	Diffuse peripheral involvement	Limited to autonomic nervous system	Central multiorgan ± peripheral
Peripheral somatic neuropathy	Frequent but mild	No	< 25% of subjects
CNS involvement	No	No	Yes
Progression	Often stable, or resolves	Slow over 10 to 15 years	More rapid; usually < 10 years
Supine plasma norepinephrine	Reduced	Reduced	Normal
EMG	May be abnormal	Normal	Usually normal
QSART	Abnormal	Abnormal	May be normal

Management

Some of the autonomic neuropathies are amenable to treatment of the underlying disease. Lambert-Eaton myasthenic syndrome usually responds to treatment of the underlying malignancy but immunosuppressive agents such as prednisone alone or in combination with azathioprine as well as plasma exchange and IVIG have been successful in improving symptoms. Aminopyridines, such as 3,4-diaminopyridine (DAP), are the mainstay of treatment and are also effective in improving autonomic function; more than 85% of patients with Lambert-Eaton myasthenic syndrome demonstrate significant clinical benefit from DAP therapy (62). Firdapse® (amifampridine) form of 3,4 DAP was approved in the United States in 2018. The results of the Diabetes Control and Complications Trial study show that improvement in glycemic control can prevent, and probably reverse, progression of diabetic autonomic pathology (17). Burden and Burden described three patients who developed weight loss and symptomatic autonomic neuropathies with diabetes (09). Each of these patients had resolution of their autonomic neuropathy in association with recovery of their normal weight, suggesting that recovery from diabetic autonomic neuropathy with weight loss should be anticipated with return to premorbid weight and glycemic control. Liver transplantation has been shown to reverse autonomic neuropathy secondary to cirrhosis (53), supporting the idea that the etiology of autonomic neuropathy in these cases likely arises from metabolic dysfunction rather than structural alteration.

IVIG has been used increasingly in the treatment of autoimmune forms of dysautonomia, typically the subacute or acute forms. However, some anecdotal or retrospective studies suggest that patients with small fiber neuropathy and autonomic dysfunction treated with intravenous immunoglobulin therapy may benefit (75). However, patients develop aseptic meningitis or severe headache, more than other patient populations (64). A recent randomized placebo-controlled trial of IVIG for 20 patients with small fiber neuropathy associated with two autoantibodies, trisulfated heparin disaccharide (TS-HDS) and fibroblast growth factor receptor 3 (FGFR-3), found no benefit (32). An earlier and larger randomized placebo-controlled study of 60 patients with idiopathic small fiber neuropathy without these antibodies in the Netherlands also showed no benefit (29).

Purinergic signaling has been shown to be involved in the regulation of cardiovascular function. Animal studies showed that P2Y12 receptor could mediate diabetic cardiac autonomic neuropathy (DCAN)-induced sympathetic reflexes. The study findings suggested that P2Y12 receptor in stellate ganglion could be a potential therapeutic target for the treatment of diabetic cardiac autonomic neuropathy (34).

Many of the diseases that lead to autonomic neuropathy cannot be treated directly; therefore, a symptomatic approach is used. Lifestyle changes can be remarkably helpful; these are geared toward placing as little stress on the autonomic nervous system as possible and involve behavioral techniques. Pharmacotherapy should only be considered when the patient's symptoms become severe and only after lifestyle changes have failed to produce adequate relief. The last tier of treatment involves consideration of surgical interventions.

Orthostatic hypotension can be one of the most debilitating symptoms of autonomic neuropathy (27). Patient education techniques include standing up slowly, avoiding large meals, elevating the head of the bed to help improve nocturnal diuresis, and avoiding early morning orthostatic hypotension. Thigh-high hose compression can reduce venous pooling; waist-high stockings are more effective in increasing standing blood pressure but are frequently too cumbersome for patients slowed by neurologic disease. Extra salt, water, and caffeine can also be added to the diet to reduce postprandial hypotension. In addition to the medications listed in Table 3, droxidopa, an orally active synthetic amino acid, has been approved by the FDA for short-term treatment of neurogenic orthostatic hypotension. It is converted to norepinephrine by the enzyme aromatic L-amino acid decarboxylase (40).

Table 3. Treatment of Orthostatic Hypotension in Autonomic Neuropathy

Medication	Dose	Notes
Fludrocortisone	0.1 to 0.5 mg daily, orally
Midodrine	5 to 10 mg three to four times daily, orally
Clonidine	0.1 to 0.3 mg two times daily, orally
Propranolol	10 to 40 mg four times daily, orally	useful with uncontrolled tachycardia
Octreotide	50 to 100 mcg three times daily, 1500 mcg per day maximum, subcutaneously
Yohimbine	2.5 to 5.4 mg three times daily, orally	Very rarely used
Droxidopa	100 to 600 mg three times daily, orally	approved for nondiabetic neurogenic orthostatic hypotension

Supine hypertension can be a paradoxical and confounding problem in some patients with orthostatic hypotension due to autonomic neuropathy. Some of these patients have been shown to develop left ventricular hypertrophy, suggesting that treatment is warranted. Avoidance of the supine position during the day and the use of short-acting vasodilators such as transdermal nitroglycerin at night can successfully combat this problem (39).

Management of autonomic dysfunction of the urinary bladder such as over distension, overflow incontinence, and bladder and sphincter dyssynergia first revolves around behavioral changes with scheduled voiding every 3 to 4 hours. Intermittent self-catheterization can be started if the patient continues to have significant postvoid residuals.

Table 4. Treatment of Neurologic Dysfunction of the Bladder

Medical treatment
		• timed voiding • night time fluid restriction • pelvic floor biofeedback
	Catheterization
		• intermittent catheterization • condom catheters • diapers and pads • indwelling catheters
	Pharmacology
		• Anticholinergic agonists used for detrusor hyperreflexia:
			- oxybutynin chloride 5 mg three times per day, orally - dicyclomine hydrochloride 20 mg three times per day - flavoxate hydrochloride 100 to 200 mg four times per day - propantheline bromide 15 to 30 mg four times per day
		• Adrenergic blocking agents used for voiding dysfunction:
			- prazosin - terazosin - doxazosin
		• Other medications for detrusor overactivity and incontinence:
			- imipramine 25 mg one to three times per day - terodiline 25 to 50 mg two times per day - diazepam - baclofen
Surgical treatment
	Operations on the detrusor muscle
		• denervation procedures for detrusor hyperreflexia • cystoplasty • ileal conduit
	Operations on the urethra
		• sphincterectomy • prostatectomy • formation of artificial sphincters

Erectile dysfunction can be managed with sildenafil with mild to no side effects. It should be avoided in patients who are taking nitrates or those who have had a recent myocardial infarction or stroke or in those with marked orthostatic hypotension. Vardenafil (10 mg single dose, orally; start at 5 mg if the patient is older than 65 years of age; one dose per day maximum) and tadalafil (10 mg single dose, orally; reduce dosage if the patient is using a potent CYP3A14 inhibitor; 20 mg per 36 hours maximum) appear to be as effective as sildenafil (50 mg single dose, orally; 25 mg if the patient is older than 65 years of age or is using potent CYP3A14 inhibitor; 100 mg per dose, one dose per day maximum), but tadalafil has a longer duration of action. Alprostadil and papaverine can be tried if sildenafil is not successful (20).

Dry eyes can be managed with the liberal use of artificial tears; in severe cases, surgical closure of the tear duct can be considered (20). Dry mouth can be treated with pilocarpine.

Gastroparesis can be managed either with erythromycin or metoclopramide. The most effective pharmacological treatment is cisapride, although it has restricted access in the United States and has serious side effects, which include cardiac arrhythmia, aplastic anemia, and hepatic toxicity. Intrapyloric injection of botulinum toxin was also shown to be effective in improving symptoms associated with diabetic gastroparesis resistant to conventional treatment (36). Tegaserod (6 mg two times per day, 30 to 60 minutes before meals, for 4 to 6 weeks) is useful in patients with irritable bowel syndrome. Loperamide can also be used to manage diarrhea if infectious causes have been eliminated. One pilot study showed pyridostigmine (cholinesterase inhibitor) improves colonic transit and symptoms in some patients with autonomic neuropathy and constipation (07). Studies have shown promising results of gastric electrical stimulation, which accelerates gastric emptying by delivering electrical currents to the stomach and may possibly become an alternative therapy for patients who are refractory to prokinetic agents (44).

Excessive tachycardia associated with postural orthostatic tachycardia syndrome can be treated with small doses of beta-blockers such as propranolol.

Botulinum toxin has been studied and found to be successful in treating some of the symptoms of autonomic dysfunction, including bladder symptoms and axillary hyperhidrosis (38). Palmar and plantar hyperhidrosis can be effectively treated with tap water iontophoresis. Other treatments include topical agents such as aluminum chloride hexahydrate and oral medications such as beta-blockers or benzodiazepines.

In inherited amyloid neuropathy (familial amyloid polyneuropathy), liver transplantation was previously thought to prevent progression of the disease. However, observations show that liver transplants may not always arrest the development of autonomic neuropathy (18). Tafamidis, a 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid, selectively binds to TTR with negative cooperativity and kinetically stabilizes wild-type native TTR and mutant TTR. Results from two initial trials indicated that the beneficial effects of tafamidis were sustained over a 30-month period and that starting treatment early is beneficial. It was initially approved in Europe in 2011 and has since been approved in other countries for early-stage TTR-FAP (72). In August 2018, patisiran (Onpattro®), a double-stranded small interfering ribonucleic acid is approved for hereditary amyloidosis by the FDA. This is the first treatment approved for hereditary transthyretin-mediated amyloidosis (HATTR) polyneuropathy and also the first treatment approved in this class of drugs called small interfering ribonucleic acid (siRNA). This works by silencing a portion of the RNA involved in causing the disease. The efficacy of patisiran was shown in a clinical trial involving 225 patients where 148 patients were randomized and received a drug infusion or placebo every 3 weeks. Patients on patisiran had better outcomes on measures of polyneuropathy (01). Trials are ongoing to assess the benefit of patisiran for treatment of cardiomyopathy.

References

01: Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin myloidosis. N Engl J Med 2018;379(1):11-21.** PMID 29972753
02: Airaksinen KE, Salmela PI. Pregnancy is not a risk factor for a deterioration of autonomic nervous function in diabetic women. Diabet Med 1993;10:540-2. PMID 8365090
03: Amar K. Progressive supranuclear palsy. Hosp Med 2003;64(10):585-8. PMID 14584237
04: Axelrod FB. Familial dysautonomia. Muscle Nerve 2004;29(3):352-56. PMID 14981733
05: Axelrod FB, Hilz MJ. Inherited autonomic neuropathies. Sem Neurol 2003;23(4):381-90. PMID 15088259
06: Bekircan-Kurt CE, Güneş N, Yılmaz A, Erdem-Özdamar S, Tan E. Three Turkish families with different transthyretin mutations. Neuromuscul Disord 2015;25(9):686-92. PMID 26115788
07: Bharucha AE, Low PA, Camilleri M, Burton D, Gehrking TL, Zinsmeister AR. Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. Clin Auton Res 2008;18(4):194-202. PMID 18622640
08: Britton JW. Syncope and seizures: differential diagnosis and evaluation. Clin Auton Res 2004;14(3):148-59. PMID 15241643
09: Burden ML, Burden AC. Resolution of diabetic autonomic neuropathy. Postgrad Med J 2002;78(920):360-1. PMID 12151692
10: Burgos LG, Ebert TJ, Asiddao C, et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989;70:591-7. PMID 2929996
11: Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain-barre syndrome: prevalence, clinical spectrum, and outcomes. Neurocrit Care 2020;32(1):113-20. PMID 31297663
12: Ciljakova M, Vojtkova J, Durdik P, et al. Cough reflex sensitivity in adolescents with diabetic autonomic neuropathy. Eur J Med Res 2009;14(Suppl 4):45-8. PMID 20156724
13: Conceicao I. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system. Clin Auton Res 2019;(Suppl 1):11-17. PMID 31399774
14: Coskun BK, Saral Y, Belirgen S, Ozturk P. Idiopathic unilateral hyperhidrosis with Holmes-Adie syndrome. J Dermatol 2004;31(6):473-6. PMID 15235187
15: Cruz MW. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review. Clin Auton Res 2019;(Suppl 1):19-24. PMID 31407119
16: Dabby R. Pain disorders and erythromelalgia caused by voltage-gated sodium channel mutations. Curr Neurol Neurosci Rep 2012;12(1):76-83. PMID 21984269
17: DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41:416-23. PMID 9562345
18: Delahaye N, Rouzet F, Sarda L, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine 2006;85(4):229-38. PMID 16862048
19: Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004;144(5 Suppl):S20-6. PMID 15126980
20: Donofrio PD, Caress JB. Autonomic disorders. The Neurologist 2001;7:220-33.
21: Echaniz-Laguna A, Altuzarra C, Verloes A, et al. NTRK1 gene-related congenital insensitivity to pain with anhidrosis: a nationwide multicenter retrospective study. Neurogenetics 2021;22(4):333-41. PMID 34405299
22: Eichler FS, Hornemann T, McCampbell A, et al. Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J Neurosci 2009;29:14646–51. PMID 19923297
23: Einarsdottir E, Carlsson A, Mind J, et al. A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum Mol Genet 2004;13(8):799-805. PMID 14976160
24: England JD, Gronseth GS, Franklin G, et al. Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve 2009;39(1):106-15. PMID 19086069
25: Escorcio-Bezerra ML, Manzano GM, Bichuetti DB, et al. Tonic pupils: an unusual autonomic involvement in chronic inflammatory demyelinating polyneuropathy (CIDP). Neurol Sci 2019;40(8):1725-7. PMID 30997592
26: Fiorillo C, Capodivento G, Geroldi A, et al. The SPTLC1 p.S331 mutation bridges sensory neuropathy and motor neuron disease and has implications for treatment. Neuropathol Appl Neurobiol 2022;48(7):e12842. PMID 35904184
27: Freeman R. Treatment of orthostatic hypotension. Semin Neurol 2003;23(4):435-42. PMID 15088264
28: Freeman R. Autonomic peripheral neuropathy. Lancet 2005;365:1259-70. PMID 15811460
29: Geerts M, de Greef BT, Sopacua M, et al. Intravenous immunoglobulin therapy in patients with painful idiopathic small fiber neuropathy. Neurology 2021;96(20):e2534-45.** PMID 33766992
30: Gibbons C, Wang N, Rajan S, et al. Cutaneous α-synuclein signatures in patients with multiple system atrophy and Parkinson disease. Neurology 2023a;100(15):e1529-39. PMID 36657992
31: Gibbons CH, Freeman R. Autonomic neuropathy and coeliac disease. J Neurol Neurosurg Psychiatry 2005;76(4):579-81. PMID 15774451
32: Gibbons CH, Rajan S, Senechal K, Hendry E, McCallister B, Levine TD. A double-blind placebo-controlled pilot study of immunoglobulin for small fiber neuropathy associated with TS-HDS and FGFR-3 autoantibodies. Muscle Nerve 2023b;67(5):363-70. PMID 36367813
33: Granberg V, Ejskjaer N, Peakman M, Sundkvist G. Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy. Diabetes Care 2005;28(8):1959-64. PMID 16043739
34: Guo J, Sheng X, Dan Y, et al. Involvement of P2Y12 receptor of stellate ganglion in diabetic cardiovascular autonomic neuropathy. Purinergic Signal 2018;14(4):345-57. PMID 30084083
35: Hagay Z, Weissman A. Management of diabetic pregnancy complicated by coronary artery disease and neuropathy. Obst Gynecol Clin N Am 1996;23:205-20. PMID 8684779
36: Hummel M, Geigenberger G, Brand J, Ziegler AG, Füchtenbusch M. New therapeutic approaches to diabetic gastroparesis. Med Klin (Munich) 2008;103(7):514-8. PMID 18604486
37: Jacobson DM, Hiner BC. Asymptomatic autonomic and sweat dysfunction in patient with Adie’s syndrome. J Neuro-Opthalmol 1998;18:143-7. PMID 9621272
38: Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75(7):951-7. PMID 15201348
39: Kauffman H, Biaggioni I. Autonomic failure in neurodegenerative disorders. Semin Neurol 2003;23:351-63.
40: Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther 2015;13(8):875-91. PMID 26092297
41: Khan M, Farver D. Recognition, assessment and management of neuroleptic malignant syndrome. S D J Med 2000;53(9):395-400. PMID 11016275
42: Kitamura A, Hoshino T, Kon T, Ogawa R. Patients with diabetic neuropathy are at risk of greater intraoperative reduction in core temperature. Anesthesiology 2000;92:1311-8. PMID 10781276
43: Lafreniere RG, MacDonald ML, Dube MP, et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the study of Canadian genetic isolates. Am J Hum Gen 2004;74(5):1064-73. PMID 25060842
44: Lin Z, Forster J, Sarosiek I, McCallum RW. Treatment of gastroparesis with electrical stimulation. Dig Dis Sci 2003;48(5):837-48. PMID 12772777
45: Lipka AF, Verschuuren JJGM. Lambert-Eaton myasthenic syndrome. Handb Clin Neurol 2024;200:307-25. PMID 38494285
46: Lischka A, Eggermann K, Record CJ, et al. Genetic landscape of congenital insensitivity to pain and hereditary sensory and autonomic neuropathies. Brain 2023;146(12):4880-90. PMID 37769650
47: LoPachin RM, Balaban CD, Ross JF. Acrylamide axonopathy revisited. Toxicol Appl Pharmacol 2003;188(3):135-53. PMID 12729714
48: Lorenzoni PJ, Bayer DL, Ducci RD, et al. Spectrum of SPTLC1-related disorders: a novel case of 'Ser331 syndrome' that expand the phenotype of hereditary sensory and autonomic neuropathy type 1A and motor neuron diseases. Neurol Sci 2023;44(7):2551-4. PMID 36964315
49: Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc 1993;68:748-52. PMID 8392653
50: Low PA, Vernino S, Suarez G. Autonomic dysfunction in peripheral nerve disease. Muscle Nerve 2003;27(6):646-61. PMID 12766975
51: Luciano CA, Russell JW, Banerjee TK, et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve 2002;26(5):622-9. PMID 12402283
52: Martinelli P. Holmes-Adie syndrome. Lancet 2000;356:1760-1. PMID 11095273
53: McDougall AJ, Davies L, McCaughan GW. Autonomic and peripheral neuropathy in endstage liver disease and following liver transplantation. Muscle Nerve 2003;28(5):595-600. PMID 14571462
54: Mead S, Reilly MM. A new prion disease: relationship with central and peripheral amyloidoses. Nat Rev Neurol 2015;11(2):90-7. PMID 25623792
55: Moraes DN, Nascimento BR, Lima-Costa MF, Soares CPM, Ribeiro ALP. Vagal dysautonomia in patients with Chagas disease and mortality: 14-year results of a population cohort of the elderly. J Electrocardiol 2024;82:1-6. PMID 37979240
56: Panayiotopoulos CP. Autonomic seizures and autonomic status epilepticus peculiar to childhood: diagnosis and management. Epilepsy Behav 2004;5(3):286-295. PMID 15145296
57: Patterson Rosa L, Walker N, Mallicote M, MacKay RJ, Brooks SA. Genomic association of chronic idiopathic anhidrosis to a potassium channel subunit in a large animal model. J Invest Dermatol 2021;141(11):2639-45. PMID 34081968
58: Peltier AC, Russell JW. Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002;15(5):633-8. PMID 12352008
59: Penno A, Reilly MM, Houlden H, et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem 2010;285(15):11178-87. PMID 20097765
60: Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249(1):9-17. PMID 11954874
61: Rozentsveig V, Katz A, Weksler N, et al. The anesthetic management of patients with congenital insensitivity to pain with anhidrosis. Paediatr Anaesth 2004;14(4):344-8. PMID 15078381
62: Sanders DB. Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 2003;998:500-8. PMID 14592920
63: Santiago S, Ferrer T, Espinosa ML. Neurophysiological studies of thin myelinated (A delta) and unmyelinated (C) fibers: application to peripheral neuropathies. Neurophysiol Clin 2000;30(1):27-42. PMID 10740794
64: Schofield JR, Chemali KR. How we treat autoimmune small fiber polyneuropathy with immunoglobulin therapy. Eur Neurol 2018;80(5-6):304-10. PMID 30889595
65: Soysal A, Atay T, Ozu T, Arpaci B. Electrophysiological evaluation of peripheral and autonomic involvement in leprosy. Can J Neurol Sci 2004;31:357-62. PMID 15376480
66: Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003;60(1):108-11. PMID 12525727
67: Tahrani AA, Dubb K, Raymond NT, et al. Cardiac autonomic neuropathy predicts renal function decline in patients with type 2 diabetes: a cohort study. Diabetologia 2014;57(6):1249-56. PMID 24623102
68: Tursi A, Giorgetti GM, Iani C. Peripheral neurological disturbances, autonomic dysfunction, and antineuronal antibodies in adult celiac disease before and after a gluten-free eiet. Dig Dis Sci 2006;51(10):1869-74. PMID 16967315
69: Verhoeven K, Coen K, De Vriendt E, et al. SPTLC1 mutation in twin sisters with hereditary sensory neuropathy type I. Neurology 2004;62(6):1001-2. PMID 15037712
70: Viana JD, Bento C, Vieira H, et al. Haemodynamics during liver transplantation in familial amyloidotic polyneuropathy: study of the intraoperative cardiocirculatory data of 50 patients. Rev Port Cardiol 1999;18:689-97. PMID 10466370
71: Vinik AI, Freeman R, Erbas T. Diabetic autonomic neuropathy. Sem Neurol 2003;23(4):365-72.
72: Waddington Cruz M, Benson MD. A review of Tafamidis for the treatment of transthyretin-related amyloidosis. Neurol Ther 2015;4(2):61-79. PMID 26662359
73: Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004;3(2):93-103. PMID 14747001
74: Yuan J, Matsuura E, Higuchi Y, et al. Hereditary sensory and autonomic neuropathy type IID caused by an SCN9A mutation. Neurology 2013;80(18):1641-9. PMID 23596073
75: Zeidman LA, Saini P, Mai P. Immune-mediated small fiber neuropathy with trisulfated heparin disaccharide, fibroblast growth factor receptor 3, or plexin d1 antibodies: presentation and treatment with intravenous immunoglobulin. J Clin Neuromuscul Dis 2022;24(1):26-37. PMID 36005471

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Former Authors

James W Russell MD MS
Mamatha Pasnoor MD
Mazen M Dimachkie MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: female>male, >2:1

male=female
Heredity: heredity typical

heredity may be a factor

autosomal dominant

autosomal recessive
Population groups selectively affected: Inherited amyloidosis: Portuguese, Japanese, and Swedish population groups

Hereditary sensory autonomic neuropathy type III: Ashkenazi-Jewish

Hereditary sensory autonomic neuropathy type IV: Israeli Arabs
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Insulin-dependent diabetes mellitus: E10.4

Secondary systemic amyloidosis: E85.3

Drug-induced polyneuropathy: G62.0

Hereditary motor and sensory neuropathy: G60.0

Idiopathic peripheral autonomic neuropathy: G90.0

Disorder of autonomic nervous system, unspecified: G90.9

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Chronic autonomic neuropathies

Associated Disorders

Adie syndrome
Amyloid neuropathy
Botulism
Chagas disease
Chronic idiopathic anhidrosis
- Chronic paraneoplastic autonomic neuropathy
- Diabetic autonomic neuropathy
- Distal sympathetic neuropathies
- Drug induced autonomic neuropathies
- Fabry disease
- HIV neuropathy
- Lambert-Eaton myasthenic syndrome
- Lepromatous neuropathy
- Pandysautonomia
- Pure adrenergic neuropathy

Differential Diagnosis

pure autonomic failure
multisystem atrophy
multiple systems atrophy
Parkinson disease
olivopontocerebellar degeneration
- progressive supranuclear palsy
- autonomic seizures
- neuroleptic malignant syndrome
- syringomyelia
- subacute combined degeneration
- multiple sclerosis
- drugs affecting autonomic regulation

Also Relevant

Acute autonomic neuropathies
Acute pandysautonomia
Botulism
Chemotherapy-induced neuropathies
Clinical evaluation of peripheral neuropathies
- Diabetic neuropathies
- Fabry disease
- Lambert-Eaton myasthenic syndrome
- Neurogastroenterology
- Neuropathy associated with leprosy

Chronic autonomic neuropathies

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Clinical Features of Autonomic Nervous System Failures

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Table 2. Distinguishing Autonomic Neuropathy From Other Causes of Autonomic Failure

Diagnostic workup

Management

Table 3. Treatment of Orthostatic Hypotension in Autonomic Neuropathy

Table 4. Treatment of Neurologic Dysfunction of the Bladder

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neuropathies associated with cytomegalovirus infection

Clinical evaluation of peripheral neuropathies

Hypothyroidism

Monoclonal gammopathy of neurologic significance

Chronic inflammatory demyelinating polyradiculoneuropathy

Amyotrophic lateral sclerosis

Amiodarone neuropathy

Autoimmune autonomic neuropathy

This is an article preview.
Start a Free Account
to access the full version.